Contract analysis

I. EXECUTIVE SUMMARY Whitmore Valuation Group LLC ("WVG") was retained by Calderwood & Harkness LLP ("C&H"), outside tax counsel to Penterra Pharmaceuticals Corp. ("PPC"), under a Kovel arrangement (Kovel letter dated June 20, 2022, reference C&H Matter No. 1018-00009-KV), to perform an independent economic analysis of the platform contribution transaction ("PCT") payment made by Penterra Biopharma International DAC

1. The $312,000,000 PCT payment is within the arm's-length range of $278,000,000 to $361,000,000 and satisfies the arm's-length standard under IRC § 482 and Treas. Reg. § 1.482-7.

2. The IRS's proposed PCT valuation of $852,000,000, based on a WACC of 7.2% and inflated revenue projections, is not within the arm's-length range and is not supportable under the best method rule set forth in Treas. Reg. § 1.482-1(c).

3. The $540,000,000 delta asserted by the IRS is attributable primarily to: (a) an inappropriately low discount rate that fails to account for pharmaceutical-specific and company-specific risk factors, and (b) revenue projections that incorporate impermissible hindsight by effectively embedding knowledge of actual product successes that was not available at the PCT date.

4. The PCT valuation is internally consistent with WVG's parallel analyses of the legacy IP royalty rate (4.5%) under the comparable uncontrolled transaction ("CUT") method and PBI's operating margins under the comparable profits method ("CPM") / transactional net margin method ("TNMM"), further confirming the arm's-length character of the PPC-PBI transfer pricing framework.

II.A. Engagement Background Penterra Pharmaceuticals Corp. PPC is a corporation organized under the laws of the State of Delaware, publicly traded on the Nasdaq Global Select Market under the ticker symbol "PPCA," with its principal executive offices located at 2200 Independence Boulevard, Princeton Junction, New Jersey 08550. PPC is a specialty pharmaceutical and biotechnology company focused on the discovery, devel

II.B. Scope of Assignment WVG was engaged to perform the following tasks:

1. PCT Valuation. Perform an independent valuation of the pre-existing intellectual property contributed to the CSA as of the PCT date (July 1, 2012) using the income method / DCF approach as prescribed by Treas. Reg. § 1.482-7(g)(4). This valuation encompasses the development and application of a DCF model incorporating product-level revenue projections, cost structure analysis, terminal value determination, and an

2. Arm's-Length Evaluation. Evaluate the appropriateness of the $312,000,000 PCT payment within the arm's-length standard, as articulated in Treas. Reg. § 1.482-1(b), by establishing an arm's-length range for the PCT value and determining whether the actual payment falls within that range.

3. Critique of IRS Valuation. Assess and critique the IRS economist's income-method valuation of $852,000,000, including the specific inputs employed by Dr. Alan Washburne, with particular focus on the IRS's discount rate (7.2% WACC), revenue projections, clinical success probability assumptions, and terminal value methodology.

4. Arm's-Length Range Determination. Determine an arm's-length range for the PCT value by performing sensitivity analyses across key valuation inputs, including the discount rate, revenue growth assumptions, and probability-weighting factors for clinical-stage compounds.

5. Consistency Analysis. Evaluate the internal consistency of the PCT valuation with WVG's parallel analyses of the legacy IP royalty rate (CUT method) and PBI's operating margins (CPM/TNMM), to confirm that the overall PPC-PBI transfer pricing framework reflects arm's-length results. This report sets forth the results of WVG's analysis and constitutes WVG's work product prepared at the direction of C&H under the Kov

II.C. Information Sources and Materials Reviewed In performing the analysis set forth in this report, WVG reviewed the following categories of documents and materials. A complete list of specific documents reviewed is set forth in Appendix A. CSA and Related Agreements. The cost-sharing arrangement agreement between PPC and PBI, effective July 1, 2012, together with all subsequent amendments thereto. The CSA agreemen

III. LEGAL AND REGULATORY FRAMEWORK

III.A. IRC § 482 and the Arm's-Length Standard

Section 482 of the Internal Revenue Code grants the Secretary of the Treasury broad authority to distribute, apportion, or allocate gross income, deductions, credits, or allowances between or among two or more organizations, trades, or businesses that are owned or controlled directly or indirectly by the same interests, if the Secretary determines that such distribution, apportionment, or allocation is necessary in o

III.B. Cost-Sharing Arrangements Under Treas. Reg. § 1.482-7 Treasury Regulation § 1.482-7 provides specific rules for qualified cost-sharing arrangements among controlled participants. A qualified CSA is an arrangement under which two or more controlled participants share the costs and risks of developing intangibles in proportion to their reasonably anticipated shares of the benefits from exploiting those intangibl

III.C. Transfer Pricing Methods for Intangible Property Under Treas. Reg. § 1.482-4 Treasury Regulation § 1.482-4 provides methods for determining the arm's-length amount charged in a controlled transaction involving the transfer of intangible property. The specified methods include the comparable uncontrolled transaction ("CUT") method (Treas. Reg. § 1.482-4(c)), the comparable profits method ("CPM") (as applied und

III.D. IRC § 367(d) Considerations

Section 367(d) of the Internal Revenue Code addresses certain transfers of intangible property by a United States person to a foreign corporation in an exchange described in Section 332, 351, 354, 356, or 361. Under Section 367(d), the U.S. transferor is treated as having transferred the intangible property in exchange for payments contingent on the productivity, use, or disposition of such property, and must include

III.E. OECD Transfer Pricing Guidelines While the OECD Transfer Pricing Guidelines for Multinational Enterprises and Tax Administrations do not have the force of law in the United States, they are recognized as persuasive authority in transfer pricing matters and provide a useful framework for economic analysis. See, e.g., Xilinx, Inc. v. Commissioner, 125 T.C. 37, 62 (2005) (noting that the OECD Guidelines are "an i

IV. DESCRIPTION OF THE PLATFORM CONTRIBUTION TRANSACTION

IV.A. CSA Structure and PCT Context The CSA between PPC and PBI was executed effective July 1, 2012. Under the CSA, PPC and PBI agreed to share the costs and risks of developing and enhancing PPC's pharmaceutical intellectual property portfolio in proportion to their respective shares of the reasonably anticipated benefits from exploiting that portfolio in their assigned territories. PPC retained the exclusive right

IV.B. Pre-Existing IP Portfolio Contributed As of the PCT date of July 1, 2012, PPC's pre-existing IP portfolio included pharmaceutical compounds at various stages of development and commercialization. The portfolio represented the accumulated results of PPC's research and development investment over more than a decade, including extensive pre-clinical and clinical work, regulatory filings, and early-stage commercial

IV.C. Cost-Sharing Ratios Under the CSA, PBI's annual share of qualified R&D costs is determined based on its share of the reasonably anticipated benefits from the CSA activity, measured by projected revenue allocations between PPC (Americas) and PBI (non-Americas). As PBI's non-Americas commercial operations expanded and revenues grew, PBI's RAB share — and thus its cost-sharing percentage — increased over time. The

IV.D. PBI's Functional Profile A key element of both the PCT valuation and the broader transfer pricing analysis is the functional profile of PBI — the functions it performs, the assets it employs, and the risks it assumes in the non-Americas territories. WVG's analysis of PBI's functional profile is based on a review of PBI's organizational structure, headcount data, board minutes, regulatory expenditure records, an

V. VALUATION METHODOLOGY: INCOME METHOD / DCF APPROACH

V.A. Selection of the Income Method WVG selected the income method under Treas. Reg. § 1.482-7(g)(4) as the best method for determining the arm's-length value of the PCT payment. This selection is consistent with the best method rule of Treas. Reg. § 1.482-1(c), which requires application of the method that provides the most reliable measure of an arm's-length result under the specific facts and circumstances. The in

V.B. DCF Framework Under the income method, the PCT value equals the present value of the expected incremental cash flows attributable to the pre-existing IP from the non-Americas territory, discounted over the useful life of the contributed intangibles at an appropriate risk-adjusted rate. The general DCF framework is expressed as follows: PCT Value = Σ [Expected Divisional Profits_t / (1 + WACC)^t] for t = 1 to n W

V.C. Projection Period and Useful Life WVG employed a 15-year explicit forecast period, spanning from the PCT date (July 1, 2012) through June 30, 2027, reflecting the estimated remaining commercial life of the contributed compounds. This projection horizon was determined based on an analysis of the following factors: Average Remaining Patent Life. As of July 1, 2012, the key compounds in the contributed portfolio ha

VI.A. Revenue Forecasting Methodology A critical input to the DCF model is the projection of revenues attributable to the contributed IP in the non-Americas territory over the 15-year forecast period. WVG's revenue projections were prepared as of the PCT date (July 1, 2012), based on information reasonably available at that time. This as-of-date framework is required by the regulations and is essential to the integri

1. Product-by-Product Analysis. Revenue projections were developed on a product-by-product basis for each compound included in the CSA portfolio, reflecting the specific clinical development status, regulatory pathway, competitive landscape, and market potential of each compound as of July 1, 2012.

2. Clinical Development Probability Adjustments. For compounds that were not yet approved as of the PCT date (i.e., Imvara, Cerulon, and other pipeline compounds), revenue projections were adjusted by probability-of-success factors reflecting the likelihood that each compound would successfully complete clinical development and obtain regulatory approval. These probability factors were based on published industry dat

3. Market Size and Penetration Estimates. For each compound, WVG estimated the total addressable market in the non-Americas territory based on epidemiological data, current treatment paradigms, and pricing and reimbursement dynamics in key non-Americas markets (EU5, Japan, China, Brazil, and other significant markets). Market penetration rates were estimated based on the compound's projected efficacy and safety profi

4. Pricing Assumptions. Pricing assumptions reflected the expected ex-manufacturer net prices in each major non-Americas market, taking into account government-controlled pricing and reimbursement systems, reference pricing mechanisms, and competitive pricing dynamics. Non-Americas prices were generally assumed to be lower than U.S. prices, consistent with observed international pharmaceutical pricing differentials.

5. Launch Timing. Projected launch dates in non-Americas markets were based on the expected timelines for regulatory submissions and approvals in the EU (EMA), Japan (PMDA), and other key markets, taking into account the typical lag between U.S. and non-U.S. approvals for pharmaceutical products.

6. Competitive Landscape Analysis. Revenue projections incorporated an assessment of the competitive landscape as of July 1, 2012, including existing and anticipated competitive products, potential generic or biosimilar entry upon patent expiration, and the expected evolution of treatment guidelines.

VI.B. Product-Level Revenue Projections Veritaxol (Oncology). At the PCT date, Veritaxol had been approved by the FDA for approximately eight months and was in the early stages of U.S. commercialization. EU regulatory filings were in progress, with EMA approval anticipated in 2013. Japanese regulatory filings were expected to follow, with PMDA approval anticipated in 2014. Veritaxol's novel mechanism of action and pr

VI.C. Comparison of WVG Projections to IRS Projections The IRS economist, Dr. Alan Washburne, developed revenue projections as part of the IRS's income-method valuation that differ materially from WVG's projections. WVG has identified the following principal areas of disagreement: Higher Revenue Growth Assumptions. Dr. Washburne's projections assume higher revenue growth rates for the contributed compounds in the non